Rigel Pharmaceuticals Says its R289 Hematology Drug Candidate Receives Fast-Track Designation From US FDA

MT Newswires Live12-02

Rigel Pharmaceuticals (RIGL) early Monday said the US Food and Drug Administration has granted fast track designation for the company's R289 drug candidate for the treatment of patients with previously treated transfusion dependent lower-risk myelodysplastic syndrome.

Myelodysplastic syndrome is a cancer that causes bone marrow to produce abnormal or immature blood cells instead of healthy ones.

The selective dual IRAK1- and IRAK4-inhibitor is currently being evaluated in a phase 1b study to determine its safety, tolerability, pharmacokinetics and preliminary activity in patients with the hematologic disorder who are relapsed or refractory to prior therapies, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment